<DOC>
	<DOCNO>NCT00192127</DOCNO>
	<brief_summary>This study ass safety bivalent vaccine two new 6:2 influenza virus reassortants healthy adult prior release trivalent vaccine ( FluMist ) containing .</brief_summary>
	<brief_title>Study Evaluate Safety Bivalent Vaccine New 6:2 Influenza Virus Reassortants Healthy Adults</brief_title>
	<detailed_description>The primary study objective ass safety bivalent vaccine two new 6:2 influenza virus reassortants healthy adult prior release trivalent vaccine ( FluMist ) contain . Safety demonstrate similar fever rate ( oral temperature ≥101°F Days 0-7 ) vaccine placebo recipient .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1849 year age ( yet reach 50th birthday ) ; In good health ; Available telephone ; Ability understand comply requirement protocol ; Signed informed consent HIPAA authorization . Any condition inactivate influenza vaccine indicate , include : chronic disorder pulmonary cardiovascular system , include asthma ; chronic metabolic disease ( include diabetes mellitus ) renal dysfunction , hemoglobinopathy require regular medical followup hospitalization precede year ; Acute febrile ( &gt; 100.0°F oral ) and/or respiratory illness , include cough sore throat , within 14 day prior enrollment ; Hypersensitivity egg egg protein ; Hypersensitivity gentamicin ; Any know immunosuppressive condition immune deficiency disease , include HIV infection , ongoing immunosuppressive therapy ; History GuillanBarré Syndrome ; Household contact immunocompromised ( participant also avoid close contact immunocompromised individual least 21 day ) ; Participation another investigational trial within 30 day prior enrollment expect enrollment another investigational trial study ; Chronic regular use antipyretic analgesic medication daily every day basis ; Notes : A daily dose 81 mg aspirin consider contraindication enrollment . Discontinuation prophylactic use antipyretic analgesic medication time enrollment fourteen day follow vaccination consider contraindication enrollment . Pregnancy , biologically capable woman ( e.g. , menses within last year ) participant agree use acceptable birth control measure determine investigator continuously three month enrol study ( biologically capable , urine pregnancy test must perform day vaccination negative result ) ; Breastfeeding lactate woman ; Administration intranasal medication within two week prior enrollment expect receipt study ; Employees investigational site family member individual involve conduct study ; Any condition opinion investigator , might interfere vaccine evaluation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>